2692624-22-7
2692624-22-7
Chemical Structure
Ceramide C6-d7
- CAS No.: 2692624-22-7
- Formula:C24H40D7NO3
- Molecular Weight:404.68
IUPAC Name: N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl-16,16,17,17,18,18,18-d7)hexanamide
InChIKey: NPRJSFWNFTXXQC-OMMXNDSESA-N
SMILES: OC[C@@H]([C@@H](/C=C/CCCCCCCCCCC([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])O)NC(CCCCC)=O
Biological Activity: Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ceramide C6-d7 | 99.0% | Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C6 Ceramide-13C2,d2 | C6 Ceramide-13C2,d2 (C6-Cer-13C2,d2) is the deuterium labeled and 13C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C6 Ceramide-d11 | 99.79% | C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C6 Ceramide | 99.82% | C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Qiu L, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. Biochem Biophys Res Commun. 2020;525(4):997-1003. [Content Brief]
- [3]. Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020;18(1):298. Published 2020 Aug 3. [Content Brief]
